GEN Exclusives

More »

GEN News Highlights

More »
Oct 21, 2010

Cerenis Closes Series C Financing with €50M

  • Cerenis Therapeutics raised €10 million (almost $14 million) in a second close of its Series C financing. This takes the total Series C funding to €50 million (about $70 million).

    The capital will support Phase II development of the lead program, CER-001, an HDL mimetic for the treatment of cardiovascular diseases. It will also support the development of other HDL therapies.

    CER-001 is an HDL mimetic and is based on natural apolipoprotein A-I (ApoA-I), the major structural protein of HDL. It is designed to regress atherosclerotic plaque. A Phase I study in acute coronary syndrome (ASC) patients was completed in May. Cerenis is also developing CER-001 for metabolic diseases, specifically as a treatment of orphan diseases in the lipid metabolism field.

    The ASC trial was a randomized, double-blind, placebo-controlled, cross-over, single rising dose study. It involved 32 dyslipidemic volunteers and showed that the drug was safe and well tolerated at dosages of up to 45 mg/kg. The study also demonstrated cholesterol mobilization at dose levels of 2 mg/kg and higher. A Phase II trial using intravascular ultrasound to assess plaque regression in post-ACS patients is planned for initiation later this year.

    The company has another HDL mimetic IV infusion candidate called CER-522, which is based on a peptide analogue of ApoA-I. It is currently in Phase I development for the treatment of aortic valve stenosis.

    Cerenis also has a Phase I, a Phase II, and a preclinical oral product in development, all for the treatment of dyslipidemia with low HDL. CER-627, which is at the Phase II stage, is a fixed-dose combination of niacin and aspirin, where the aspirin dose is delivered by sustained release several hours before the niacin dose. In a proof-of-concept clinical study a 39% flushing reduction compared to Niaspan, the market leader, was observed.

    Additionally, CER-628 is being developed as a statin/niacin/aspirin follow-up compound to CER-627. Cerenis is currently conducting preclinical investigations. The combination is expected to combine the attributes of CER-627 of enhancing HDL levels and reducing flushing with the LDL-lowering properties of a statin.

    In Phase I development is CER-002, which was developed from NCEs that are specific agonists for human PPAR delta. It was selected from a series of small molecule compounds available to Cerenis through a licensing agreement with Nippon Chemiphar. Cerenis says that it is exploring several orphan drug indication development pathways.

    In preclinical models CER-002 demonstrated strong efficacy in elevating HDL and in halting the progression of atherosclerosis. It also completed Phase I trials demonstrating that the product is well tolerated and safe at all doses tested.

     


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Eyes on the Science Prizes

The proliferation of big-money science prizes might be seen as cheering or worrisome. Where do you stand?